John and Connie Anderson filed the lawsuit against GSK after Mr. Anderson took Avandia and suffered eye hemorrhages and a stroke. The Andersons’ lawsuit alleges that the injuries were side effects were caused by his use of the drug.

A 2007 study published in the New England Journal of Medicine found that Avandia users face a much higher risk for serious side effects such as stroke and heart attack than patients using the diabetes drug Actos. Researchers found that patients using Avandia are up to 64% more likely to die from heart problems.

The lawsuit will resolve lawsuits filed as early as 2007, when a study in the New England Journal of Medicine revealed a link between Avandia and an increased risk of fatal heart complications. The study found Avandia increases the risk of death from heart problems by 64%.

The Food and Drug Administration issued a black box warning less than two weeks after the release of the study. A later study found that Avandia increases the risk of bone fractures in women, prompting a second black box warning from the FDA. Despite the risks associated with the drug, the FDA has not announced any plans for an Avandia recall.

The FDA issued two black box warnings to Avandia before ordering the restrictions to be placed on the drug. Under the new guidelines, Avandia will only be available to patients who have already been successfully treated with it, informed of its risks and do not respond to other medications.

The top-selling diabetes drug was first linked to an increased risk of severe side effects in 2007. In a study of more than 28,000 patients, those who used Avandia were 43% more likely to suffer a heart attack while using Avandia and 64% more likely to die from heart problems.

According to a study cited by the FDA, patients who take Actos for more than one year or at the highest dose are about 40% more likely to develop bladder cancer. Although the agency has not announced plans to issue an Actos recall, health officials in France and Germany have already order a halt to sales in their countries because of the risk of bladder cancer.

The FDA has advised doctors not to prescribe Actos to patients with active bladder cancer, and to use caution when prescribing it to patients with a history of the disease. Patients who are talking Actos were advised to talk with their doctor if they experience any symptoms of bladder cancer, including blood in the urine, urinary urgency, lower back pain or abdominal pain.

In May 2011, the Food and Drug Administration announced that Avandia would no longer be available for sale at retail pharmacies in the U.S. starting in November 2011. The agency decided to pull Avandia from retail stores after multiple studies found that the drug increased the risk of heart attack and congestive heart failure compared to other diabetes drugs.

About 12,000 Avandia users have filed lawsuits against GSK since news about the health risks associated with the drug were made public. Based on money set aside by the company to settle these lawsuits, GSK could eventually pay as much as $7 billion to settle these cases.

Once among the top-selling diabetes drugs in the world, concerns about the safely of Avandia first arose in 2007, when a study published in the New England Journal of Medicine found that patients taking the drug were more likely to suffer a heart attack or die from cardiovascular problems.

The Food and Drug Administration recently announced that it would withdraw Avandia from sale in pharmacies in the U.S. beginning in November 2011. The FDA’s move came just months after GSK announced that it would add stronger warnings to Avandia’s label. Health officials in Europe have already issued an Avandia recall over concerns about the side effects of the drug.

Wilson is seeking $5000 for each violation of South Carolina’s unfair trade practices act and $2000 for each false claim made in connection with Medicaid prescriptions. It is unclear as to the total damages that South Carolina is seeking as part of its lawsuit against Avandia.

Under the new program, only certified doctors will be allowed to prescribe Avandia to patients who have been informed about the health risks of the drug. Patients will have to fill these prescriptions through special online pharmacies, rather than retail stores.

Concerns about the health risks of Avandia first arose in 2007, when a study published by the New England Journal of Medicine found that patients were more likely to suffer a heart attack or stroke than with other diabetes drugs. An FDA drug safety expert reported that Avandia had caused heart problems or death in between 66,000 and 200,000 patients.

In June 2010, an FDA advisory committee voted to issue an Avandia recall because of the side effects risk associated with the drug. In September of that year, the agency announced that it would place new restrictions on Avandia, which were contained in today’s announcement.

Currently, there are about 5,300 lawsuits over Avandia pending in U.S. courts. Settlement talks in Los Angeles have already resulted in about 1,600 Avandia lawsuits being settled. Glaxo has previously paid about $700 million to settle about 12,000 lawsuits filed by former Avandia users.

In September 2010, Glaxo said that it would stop promoting Avandia for sale after health regulators announced that the drug would be withdrawn in Europe due to the increased risk of heart attack and other cardiovascular problems. Although the Food and Drug Administration did not issue an Avandia recall, the agency placed strong restrictions on the drug which could limit the number of patients who take Avandia instead of similar medications like Actos.

The decision to settle the thousands of Avandia lawsuits slated for hearings in Philadelphia came one month after GlaxoSmithKline settled another 700 cases for around $60 million. Experts have estimated that the company could face as many as 13,000 lawsuits against Avandia.

Concerns about the side effects of Avandia first arose in 2007, when a study found that the drug could increase the risk of heart attack and cardiovascular-related death. The Food and Drug Administration voted to place severe restrictions on the sale of Avandia in 2010, and will consider placing further restrictions on the drug in July.

Researchers in the BMJ study analyzed the medical histories of 810,000 patients who were taking Avandia or Actos. They found that Avandia users were 23% more likely to suffer congestive heart failure than patients taking Actos. Researchers also found that patients taking Avandia were 16% more likely to suffer a heart attack and 14% more likely to die while taking the drug than Actos users.

Based on their findings, researchers concluded that for every 100,000 patients taking Avandia, there would be an extra 431 deaths compared to Actos, as well as 170 extra heart attacks and 649 additional cases of heart failure. Despite these warnings, the Food and Drug Administration has not announced plans to issue an Avandia recall.